# Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia

> **NCT01358253** · PHASE4 · COMPLETED · sponsor: **Ruijin Hospital** · enrollment: 100 (actual)

## Conditions studied

- Acute Lymphoblastic Leukemia

## Interventions

- **DRUG:** Cyclophosphamide
- **DRUG:** Doxorubicin
- **DRUG:** Vincristine
- **DRUG:** Dexamethasone
- **DRUG:** Cytarabine
- **DRUG:** Methotrexate
- **DRUG:** Rituximab
- **DRUG:** 6-Mercaptopurine
- **DRUG:** Prednisone
- **DRUG:** L-asparaginase

## Key facts

- **NCT ID:** NCT01358253
- **Lead sponsor:** Ruijin Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2014-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01358253

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01358253, "Rituximab Plus Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01358253. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*